A Phase 1 interventional study of AMG 986 IV and AMG 986 PO in Heart Failure and Healthy Volunteer, sponsored by Amgen. Terminated at 25 sites in 9 countries. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-08-08.
Sponsored by Amgen · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Heart Failure by Amgen — 1 open to participants now, 1 under way, 1 of them phase 3. Heart Failure · Amgen.
Among the 11 studies in Heart Failure by Amgen, this one is the only one that started in 2016, is one of 2 in phase 1, and was the 7th registered.
6,339 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →1 of the 11 studies in Heart Failure by Amgen is open now, in 12 countries. Recruiting first, the newest first:
Amgen · Sites in United States, Argentina, Australia and 32 more countries
Ages 18–99
By country, each count listing its studies:
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 3 · Phase 4 1
First in 2002; this study’s year is marked. 1 started in 2016.
This study's enrollment of 182 is above the median of 76 across 4,052 interventional studies indexed under Heart Failure.
Median enrollment 150 across the 9 interventional studies. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Heart Failure by Amgen, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the safety and tolerability of ascending single (Part A) and ascending multiple (Part B) doses of AMG 986 in healthy adults and of ascending multiple oral doses of AMG 986 in heart failure patients (Part C).
This study is a randomized, placebo-controlled, double-blind, single day ascending dose (SDAD) study (Part A), a multiple daily ascending dose (MDAD) study (Part B), in healthy adults, and a MDAD study (Part C) in heart failure patients. In Parts A and B of the study, healthy volunteers will receive AMG 986 by continuous IV infusion or by oral administration in a fasted state. IV Infusions will be divided into an initial loading dose (LD) for the first hour followed immediately by a maintenance dose (MD).
In Part C of the study, patients with heart failure and either reduced (HFrEF) or preserved (HFpEF) ejection fraction will receive MDAD of AMG 986 or matching placebo once daily by oral administration for 21 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For Part C
Additional Inclusion Criteria for HFrEF Patients:
Additional Inclusion Criteria for HFpEF patients:
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy participants were administered placebo either intravenously (IV) or by mouth (PO) to match the 5 IV cohorts and 6 PO cohorts of AMG 986.
Drug: Placebo PO · Drug: Placebo IV
Healthy participants were administered a single dose of AMG 986 either IV or PO. The 5 IV cohorts started at a 0.5 mg loading dose over one hour up to to the Cohort 5 IV dosage consisting of a 60 mg loading dose over 1 hour and a 360 mg maintenance dose lasting 23 hours. The 6 PO cohorts started at a single 5 mg dose up to the Cohort 6 PO dose of 650 mg.
Drug: AMG 986 IV · Drug: AMG 986 PO
Healthy participants were administered placebo either IV for 4 consecutive days or PO for 7 days to match the 2 IV cohorts and 6 PO cohorts of AMG 986.
Drug: Placebo PO · Drug: Placebo IV
Healthy participants were administered AMG 986 either IV or PO. IV cohort 1 was administered a loading dose of 6 mg over one hour followed by maintenance doses of 36 mg lasting 23 hours on Day 1 and 38 mg lasting 24 hours on Days 2-4. IV cohort 2 was administered a loading dose of 60 mg over one hour followed by maintenance doses of 360 mg lasting 23 hours on Day 1 and 376 mg lasting 24 hours on Days 2-4. The 6 PO cohorts started at 5 mg for 7 days up to Cohort 6 PO dose of 650 mg for 7 days.
Drug: AMG 986 IV · Drug: AMG 986 PO
Participants with heart failure with reduced ejection fraction (HFrEF) were administered a single PO placebo tablet daily from Days 1-21.
Drug: Placebo PO
Participants with heart failure with preserved ejection fraction (HFpEF) were administered a single PO placebo tablet daily from Days 1-21.
Drug: Placebo PO
Participants with heart failure with reduced ejection fraction (HFrEF) were administered a single PO AMG 986 tablet daily from Days 1-21 in ascending doses of 10 mg for Days 1-7, 30 mg for Days 8-14 and 100 mg for days 15-21.
Drug: AMG 986 PO
Participants with heart failure with preserved ejection fraction (HFpEF) were administered a single PO AMG 986 tablet daily from Days 1-21 in ascending doses of 10 mg for Days 1-7, 30 mg for Days 8-14 and 100 mg for days 15-21.
Drug: AMG 986 PO
AMG 986 solution for infusion
AMG 986 tablets for oral (PO) administration
Matching placebo tablets for oral administration
Matching placebo solution for infusion
Participants With Treatment Emergent Adverse Events (TEAE)
An adverse event is defined as any untoward medical occurrence in a clinical trial subject. The event does not necessarily have a causal relationship with study treatment. Events categorized as TEAEs started on or after first dose of study drug and include up to 30 days after the last dose. A serious AE is an AE that met one or more of the following criteria: * Death * Life-threatening * Required inpatient hospitalization or prolongation of an existing hospitalization * Resulted in persistent or significant disability/incapacity * A congenital anomaly/birth defect * Important medical events that required medical or surgical intervention to prevent one of the outcomes above.
Time frame: Part A: Day 1 up to Day 31 Part B: Day 1 up to Day 37 Part C: Day 1 up to Day 51
Left Ventricular Ejection Fraction by Visit for Part C Heart Failure With Reduced Ejection Fraction (HFrEF) Cohort
Heart failure (HF) refers to a clinical condition in which the cardiac output is insufficient to meet the metabolic needs of body organs and is marked by cardiac systolic and/or diastolic dysfunction. Heart failure with predominantly systolic dysfunction, which is identifiable as decreased contraction, is more aptly described as heart failure with reduced ejection fraction (HFrEF). Ejection fraction is a measurement, expressed as a percentage, of how much blood the left ventricle pumps out with each contraction and is measured by echocardiogram.
Time frame: Baseline (Day 1 predose), Day 8, Day 15, Day 21, Day 30
Stroke Volume (Method of Disks, Volumetric Assessment) by Visit for Part C Heart Failure With Reduced Ejection Fraction (HFrEF) Cohort
Stroke volume is the amount of blood pumped by the left ventricle of the heart in one contraction reported by volumetric method of disks (MoD) assessment.
Time frame: Baseline (Day 1 predose), Day 8, Day 15, Day 21, Day 30
Stroke Volume (Left Ventricular Outflow Tract Using Doppler Assessment) by Visit for Part C Heart Failure With Reduced Ejection Fraction (HFrEF) Cohort
Stroke volume is the amount of blood pumped by the left ventricle of the heart in one contraction as measured using left ventricular outflow tract (LVOT) Doppler assessment.
Time frame: Baseline (Day 1 predose), Day 8, Day 15, Day 21, Day 30
Participants were enrolled at 13 study centers in 7 countries (Canada, France, New Zealand, Netherland, Poland, Singapore, United States). The study included Parts A, B (healthy volunteers) and C (participants with either heart failure with reduced ejection fraction \[HFrEF\] or heart failure with preserved ejection fraction \[HFpEF\]). Each part of the study consisted of ascending dose cohorts.
| Milestone | Part A: Placebo Pooled | Part A: AMG 986 Pooled | Part B: Placebo Pooled | Part B: AMG 986 Pooled | Part C: HFrEF Placebo | Part C: HFpEF Placebo | Part C: HFrEF AMG 986 | Part C: HFpEF AMG 986 |
|---|---|---|---|---|---|---|---|---|
| Started | 22 | 66 | 16 | 50 | 7 | 1 | 17 | 3 |
| Treated participants | 22 | 66 | 16 | 50 | 7 | 1 | 16 | 3 |
| Completed | 22 | 66 | 14 | 45 | 6 | 1 | 15 | 2 |
| Not completed | 0 | 0 | 2 | 5 | 1 | 0 | 2 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Decision by sponsor | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 1 |
An adverse event is defined as any untoward medical occurrence in a clinical trial subject. The event does not necessarily have a causal relationship with study treatment. Events categorized as TEAEs started on or after first dose of study drug and include up to 30 days after the last dose. A serious AE is an AE that met one or more of the following criteria: * Death * Life-threatening * Required inpatient hospitalization or prolongation of an existing hospitalization * Resulted in persistent or significant disability/incapacity * A congenital anomaly/birth defect * Important medical events that required medical or surgical intervention to prevent one of the outcomes above.
| Participants | Part A: Placebo Pooled | Part A: AMG 986 Pooled | Part B: Placebo Pooled | Part B: AMG 986 Pooled | Part C: HFrEF Placebo | Part C: HFpEF Placebo | Part C: HFrEF AMG 986 | Part C: HFpEF AMG 986 |
|---|---|---|---|---|---|---|---|---|
| All treatment-emergent adverse events (TEAEs) | 3 | 11 | 2 | 7 | 2 | 1 | 6 | 3 |
| Serious adverse events | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| TEAEs leading to discontinuation of study drug | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Fatal adverse events | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Heart failure (HF) refers to a clinical condition in which the cardiac output is insufficient to meet the metabolic needs of body organs and is marked by cardiac systolic and/or diastolic dysfunction. Heart failure with predominantly systolic dysfunction, which is identifiable as decreased contraction, is more aptly described as heart failure with reduced ejection fraction (HFrEF). Ejection fraction is a measurement, expressed as a percentage, of how much blood the left ventricle pumps out with each contraction and is measured by echocardiogram.
| percent of total left ventricular blood | Part C: HFrEF Placebo | Part C: HFrEF AMG 986 |
|---|---|---|
| Baseline | 33.300 ± 8.420 | 28.380 ± 6.483 |
| Day 8 | 34.900 ± 12.441 | 32.553 ± 7.055 |
| Day 15 | 33.533 ± 9.194 | 31.614 ± 7.154 |
| Day 21 | 33.550 ± 8.896 | 31.436 ± 5.953 |
| Day 30 | 33.171 ± 8.140 | 31.987 ± 7.036 |
Stroke volume is the amount of blood pumped by the left ventricle of the heart in one contraction reported by volumetric method of disks (MoD) assessment.
| mL | Part C: HFrEF Placebo | Part C: HFrEF AMG 986 |
|---|---|---|
| Baseline | 53.387 ± 16.995 | 40.461 ± 14.193 |
| Day 8 | 55.185 ± 19.158 | 46.130 ± 13.927 |
| Day 15 | 52.673 ± 19.514 | 46.784 ± 14.348 |
| Day 21 | 54.113 ± 18.789 | 44.014 ± 12.051 |
| Day 30 | 53.621 ± 19.258 | 44.634 ± 13.491 |
Stroke volume is the amount of blood pumped by the left ventricle of the heart in one contraction as measured using left ventricular outflow tract (LVOT) Doppler assessment.
| mL | Part C: HFrEF Placebo | Part C: HFrEF AMG 986 |
|---|---|---|
| Baseline | 59.056 ± 18.120 | 54.739 ± 14.523 |
| Day 8 | 52.657 ± 13.231 | 53.512 ± 14.943 |
| Day 15 | 53.985 ± 21.580 | 53.073 ± 14.747 |
| Day 21 | 55.805 ± 26.127 | 53.858 ± 14.339 |
| Day 30 | 55.113 ± 20.900 | 50.616 ± 14.212 |
Collected over Part A: Day 1 up to Day 31 Part B: Day 1 up to Day 37 Part C: Day 1 up to Day 51. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: Placebo Pooled | 0/22 (0%) | 0/22 (0%) | 3/22 (13.6%) |
| Part A: AMG 986 Pooled | 0/66 (0%) | 0/66 (0%) | 8/66 (12.1%) |
| Part B: Placebo Pooled | 0/16 (0%) | 0/16 (0%) | 2/16 (12.5%) |
| Part B: AMG 986 Pooled | 0/50 (0%) | 0/50 (0%) | 7/50 (14%) |
| Part C: HFrEF Placebo | 0/7 (0%) | 0/7 (0%) | 2/7 (28.6%) |
| Part C: HFpEF Placebo | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Part C: HFrEF AMG 986 | 0/17 (0%) | 0/16 (0%) | 6/16 (37.5%) |
| Part C: HFpEF AMG 986 | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Event | Part A: Placebo Pooled | Part A: AMG 986 Pooled | Part B: Placebo Pooled | Part B: AMG 986 Pooled | Part C: HFrEF Placebo | Part C: HFpEF Placebo | Part C: HFrEF AMG 986 | Part C: HFpEF AMG 986 |
|---|---|---|---|---|---|---|---|---|
| Pleuritic painRespiratory, thoracic and mediastinal disorders | 0/22 | 0/66 | 0/16 | 0/50 | 0/7 | 0/1 | 0/16 | 1/3 |
| Event | Part A: Placebo Pooled | Part A: AMG 986 Pooled | Part B: Placebo Pooled | Part B: AMG 986 Pooled | Part C: HFrEF Placebo | Part C: HFpEF Placebo | Part C: HFrEF AMG 986 | Part C: HFpEF AMG 986 |
|---|---|---|---|---|---|---|---|---|
| DizzinessNervous system disorders | 0/22 | 0/66 | 0/16 | 0/50 | 0/7 | 1/1 | 2/16 | 1/3 |
| NauseaGastrointestinal disorders | 0/22 | 1/66 | 0/16 | 1/50 | 0/7 | 0/1 | 1/16 | 1/3 |
| Oral mucosal eruptionGastrointestinal disorders | 0/22 | 0/66 | 0/16 | 0/50 | 0/7 | 0/1 | 0/16 | 1/3 |
| AstheniaGeneral disorders | 0/22 | 0/66 | 0/16 | 0/50 | 0/7 | 0/1 | 0/16 | 1/3 |
| Upper respiratory tract infectionInfections and infestations | 0/22 | 0/66 | 1/16 | 0/50 | 0/7 | 0/1 | 0/16 | 1/3 |
| HypoglycaemiaMetabolism and nutrition disorders | 0/22 | 0/66 | 0/16 | 0/50 | 0/7 | 0/1 | 0/16 | 1/3 |
| HypokalaemiaMetabolism and nutrition disorders | 0/22 | 0/66 | 0/16 | 0/50 | 0/7 | 0/1 | 0/16 | 1/3 |
| HypomagnesaemiaMetabolism and nutrition disorders | 0/22 | 0/66 | 0/16 | 0/50 | 0/7 | 0/1 | 0/16 | 1/3 |
| HypotensionVascular disorders | 0/22 | 0/66 | 0/16 | 0/50 | 0/7 | 0/1 | 0/16 | 1/3 |
| Swelling of eyelidEye disorders | 0/22 | 0/66 | 0/16 | 0/50 | 1/7 | 0/1 | 0/16 | 0/3 |
| Age, Continuous(years) | Part A: Placebo Pooled | Part A: AMG 986 Pooled | Part B: Placebo Pooled | Part B: AMG 986 Pooled | Part C: HFrEF Placebo | Part C: HFpEF Placebo | Part C: HFrEF AMG 986 | Part C: HFpEF AMG 986 | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 37.2 ± 9.4 | 39.5 ± 9.8 | 36.9 ± 10.0 | 37.4 ± 9.8 | 61.6 ± 10.1 | 73.0 | 64.3 ± 7.8 | 69.0 ± 1.0 | 42.3 ± 13.4 |
| Age, Customized(Participants) | Part A: Placebo Pooled | Part A: AMG 986 Pooled | Part B: Placebo Pooled | Part B: AMG 986 Pooled | Part C: HFrEF Placebo | Part C: HFpEF Placebo | Part C: HFrEF AMG 986 | Part C: HFpEF AMG 986 | Total |
|---|---|---|---|---|---|---|---|---|---|
| 18-64 years | 22 | 66 | 16 | 50 | 4 | 0 | 11 | 0 | 169 |
| 65-84 years | 0 | 0 | 0 | 0 | 3 | 1 | 6 | 3 | 13 |
| 85 years and over | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Part A: Placebo Pooled | Part A: AMG 986 Pooled | Part B: Placebo Pooled | Part B: AMG 986 Pooled | Part C: HFrEF Placebo | Part C: HFpEF Placebo | Part C: HFrEF AMG 986 | Part C: HFpEF AMG 986 | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 7 | 0 | 1 | 3 | 1 | 3 | 2 | 17 |
| Male | 22 | 59 | 16 | 49 | 4 | 0 | 14 | 1 | 165 |
| Ethnicity (NIH/OMB)(Participants) | Part A: Placebo Pooled | Part A: AMG 986 Pooled | Part B: Placebo Pooled | Part B: AMG 986 Pooled | Part C: HFrEF Placebo | Part C: HFpEF Placebo | Part C: HFrEF AMG 986 | Part C: HFpEF AMG 986 | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 6 | 22 | 1 | 5 | 1 | 0 | 0 | 0 | 35 |
| Not Hispanic or Latino | 16 | 44 | 15 | 45 | 6 | 1 | 17 | 2 | 146 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Race/Ethnicity, Customized(Participants) | Part A: Placebo Pooled | Part A: AMG 986 Pooled | Part B: Placebo Pooled | Part B: AMG 986 Pooled | Part C: HFrEF Placebo | Part C: HFpEF Placebo | Part C: HFrEF AMG 986 | Part C: HFpEF AMG 986 | Total |
|---|---|---|---|---|---|---|---|---|---|
| Asian | 3 | 6 | 6 | 11 | 2 | 0 | 2 | 0 | 30 |
| Black | 5 | 16 | 5 | 17 | 2 | 0 | 7 | 2 | 54 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| White | 11 | 35 | 5 | 18 | 3 | 1 | 8 | 0 | 81 |
| Other | 1 | 8 | 0 | 3 | 0 | 0 | 0 | 1 | 13 |
| Multiple | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.
Data sharing details ↗ · www.amgen.com
Ran from Aug 2016 to primary completion in Apr 2019, 32 months.
Results were first posted in Aug 2022, 3 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.